Drugs
Conditions
News and resources
MIMS Supported ResourcesEvaluating and treating small cell lung cancer
SCLC accounts for less than 15% of newly diagnosed lung cancers and can be distinguished from NSCLC by a high cell turnover rate and a rapidly progressive disease course, with a median survival of 3 months without treatment in extensive disease
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.